• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/4/25 5:06:08 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    mtex-20250604
    FALSE000105635800010563582024-06-132024-06-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Date of report (Date of earliest event reported): June 4, 2025
    MANNATECH, INCORPORATED
    (Exact Name of Registrant as Specified in its Charter)
    Texas000-2465775-2508900
    (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

    1410 Lakeside Parkway, Suite 200
    Flower Mound, Texas 75028
    (Address of Principal Executive Offices, including Zip Code)

    Registrant’s Telephone Number, including Area Code: (972) 471-7400
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities Registered Pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock,par value $0.0001 per shareMTEXThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
    [ ] Emerging Growth Company

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]




    Item 5.07 Submission of Matters to a Vote of Security Holders
    Mannatech, Incorporated (the “Company”) held its 2025 Annual Shareholders’ Meeting (the "Meeting") on June 3, 2025. The Company’s shareholders considered four proposals, each of which were described in the Proxy Statement. A total of 1,478,342 shares were represented in person or by proxy at the Meeting, or approximately 77.8% of the total shares outstanding. The final results of votes with respect to the proposals submitted for shareholder vote at the Meeting are set forth below.
    Proposal 1 - Election of Directors
    Shareholders elected J. Stanley Fredrick and Tyler J. Rameson as Class II directors.
    DirectorForWithheldBroker Non-Votes
    J. Stanley Fredrick996,41059,239422,693
    Tyler J. Rameson985,67169,978422,693

    Proposal 2 - Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
    Shareholders ratified the appointment of BDO USA, P.C. as the Company’s independent public accounting firm for the fiscal year ending December 31, 2025.
    ForAgainstAbstain
    1,423,47853,8351,029

    Proposal 3 - Approval, on an advisory basis, of Executive Compensation (“Say-on-Pay”)
    Shareholders approved, on an advisory basis, executive compensation.
    ForAgainstAbstainBroker Non-Votes
    1,039,9868,6207,043422,693

    Proposal 4 - Approval, on an advisory basis, frequency of future votes on Executive Compensation (“Say-on-Frequency”)
    Shareholders approved, on an advisory basis, executive compensation.
    1 Year2 Years3 YearsAbstainBroker Non-Votes
    774,408619280,406216422,693

    Item 9.01 Financial Statements and Exhibits    
    Exhibit NumberDescription
    99.1*
    Press Release, dated June 4, 2025, titled "Mannatech Announces Results of Annual Shareholders' Meeting".
    *Furnished herewith.








    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: June 4, 2025
    MANNATECH, INCORPORATED
    By:/s/ Landen Fredrick
    Landen Fredrick
    Chief Executive Officer




    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fredrick J Stanley

      4 - MANNATECH INC (0001056358) (Issuer)

      6/5/25 2:34:53 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by President and CEO Fredrick Landen Granvel

      4 - MANNATECH INC (0001056358) (Issuer)

      6/5/25 2:34:36 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by General Counsel Barta Erin Kemmler

      4 - MANNATECH INC (0001056358) (Issuer)

      6/5/25 2:34:21 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

      6/5/25 2:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

      6/5/25 2:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      6/4/25 5:06:08 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care